2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Clinical Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Devices, Surgical, Women’s Health, Biological Processes, Pathogenesis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, VWD, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4810 Win statistics for assessing marstacimab treatment effect in hemophilia

Wenquan Wang, PhD, Pengling Sun, PhD2, Bryan McComb, PhD3, Delphine Agathon, PhD4, Travis Gould, PhD5, Jasmine Healy, PhD6, Bo Huang, PhD7
1 Pfizer Inc., Collegeville, Pennsylvania, United States
2 Pfizer Inc., Cambridge, Massachusetts, United States
3 Pfizer Inc., New York, New York, United States
4 Pfizer Inc., Paris, France
5 Pfizer Inc., New York, New York, United States
6 Pfizer Canada ULC, Kirkland, Canada
7 Pfizer Inc., New York, New York, United States

Background: Despite prophylaxis with factor and non-factor therapies, many patients with hemophilia A or B continue to experience breakthrough bleeds, with treatment effects typically being assessed one endpoint at a time. Annualized bleeding rate (ABR) is the conventional metric across hemophilia trials by which the success of a treatment is measured, though this endpoint is not without limitation. Win statistics, including win ratio (WR), win odds (WO), and net benefit (NB), use generalized pairwise comparisons to combine multiple prioritized outcomes, including patient-reported outcomes, into a single composite endpoint. Marstacimab (HYMPAVZI®) is a monoclonal antibody that works by targeting the tissue factor pathway inhibitor (TFPI) and is administered as a simple once-weekly subcutaneous injection through a pre-filled pen, and it was approved in many countries/regions based on ABR from the phase 3 BASIS study (NCT03938792) in hemophilia. We apply win statistics to this study to evaluate treatment effect of marstacimab from a different angle.

Methods: In this open-label study, subjects received marstacimab during a 12-month active treatment phase and factor based replacement or bypassing therapy during a 6-month observational lead-in phase. Endpoints were prioritized hierarchically based on clinical meaningfulness—in the order of treated annualized bleeding rate (ABRtrt), spontaneous ABR, and joint ABR. In Win statistics, winning percentages from pairwise comparisons between marstacimab treatment and comparator are calculated based on the three endpoints, where a win is defined where an ABR is smaller. WR, WO, and NB with 95% CIs were estimated using the R WINS package across three cohorts: non-inhibitor with prior routine prophylaxis (non-inferiority [NI] testing), non-inhibitor with prior on-demand treatment (superiority testing), and inhibitor cohort with prior on-demand treatment (superiority testing). For the non-inferiority (NI) testing, a value that equals to the NI margin was added to the comparator ABRs. Sensitivity analysis was performed assessing different hierarchical orders of the endpoints.

Results: In the non-inhibitor prior on-demand cohort, win statistics (95% CI) strongly favored the study drug (WR 29.83 [11.83-75.21]; WO 26.23 [10.49-65.57]; NB 0.93 [0.47-1.38]; P<0.0001) which correspond to winning percentage of 96.5% in marstacimab vs 3.2% in comparator; the inhibitor cohort showed a similarly large benefit (WR 23.74 [11.20-50.32]; WO 20.74 [9.87-43.56]; NB 0.91 [0.54-1.28]; P<0.0001), indicating winning percentage was at least 90% more in the marstacimab treatment compared to on-demand treatment. In the non-inhibitor prior routine prophylaxis cohort, effects were modest but significant (WR 2.63 [1.73-3.99]; WO 2.63 [1.73-3.99]; NB 0.45 [0.24-0.66]; P<0.0001) indicating a subject on marstacimab was over 2.6 times more likely to have a similar or better outcome than when on factor prophylaxis. All p-values were 2-sided. Results were consistent across alternative endpoint orderings.

Conclusions: Win statistics provided a single, clinically interpretable benefit measure combining efficacy endpoints across all three cohorts, offering a more holistic view. The approach detected pronounced benefit of marstacimab in the non-inhibitor and inhibitor cohorts compared with prior on-demand treatment and appropriately reflected the modest effect in non-inhibitor patients already on routine prophylaxis, supporting its use for treatment effect assessment in hemophilia or rare disease trials.

Wenquan Wang, PhD: Pfizer Inc. - Current equity holder in publicly-traded company; Pfizer Inc. - Current Employment